Insight

Elad Sharon: Quite promising for c-MET over-expressing NSCLC

Photo from Elad Sharon/X

Aug 29, 2024, 17:01

Elad Sharon: Quite promising for c-MET over-expressing NSCLC

Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, adding:

“Wow! This looks quite promising for c-MET over-expressing NSCLC! Let the march of ADCs continue in oncology!”

Quoting Giuseppe Banna’s post:

“The Phase II LUMINOSITY trial shows promising results for Telisotuzumab Vedotin in treating c-Met protein–overexpressing advanced NSCLC, especially in patients with high c-Met expression.”

Giuseppe Banna

“Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.”

Authors: Ross Camidge, Jair Bar, Hidehito Horinouchi, Christine Ratajczak, Shun Lu et al.

Giuseppe Banna

Sources: Elad Sharon/X and Giuseppe Banna/X

ADC cancer Christine Ratajczak Dana-Farber Cancer Institute Elad Sharon Giuseppe Banna Hidehito Horinouchi Jair Bar LUMINOSITY trial NSCLC OncoDaily Oncology Portsmouth Hospitals University NHS Trust Ross Camidge Shun Lu Telisotuzumab Vedotin

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage